Iterum Therapeutics (NASDAQ:ITRM) Cut to Sell at Wall Street Zen

Iterum Therapeutics (NASDAQ:ITRM) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Iterum Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Iterum Therapeutics Price Performance

ITRM opened at $0.60 on Friday. The firm has a market cap of $29.07 million, a P/E ratio of -0.71 and a beta of 3.09. Iterum Therapeutics has a 1-year low of $0.57 and a 1-year high of $3.02. The company has a 50 day simple moving average of $0.69 and a two-hundred day simple moving average of $0.85.

Iterum Therapeutics (NASDAQ:ITRM) last released its earnings results on Tuesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Equities analysts anticipate that Iterum Therapeutics will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Iterum Therapeutics

A hedge fund recently bought a new stake in Iterum Therapeutics stock. Jane Street Group LLC purchased a new stake in shares of Iterum Therapeutics PLC (NASDAQ:ITRM) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 92,943 shares of the company’s stock, valued at approximately $92,000. Jane Street Group LLC owned approximately 0.21% of Iterum Therapeutics at the end of the most recent reporting period. 9.21% of the stock is currently owned by hedge funds and other institutional investors.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.